Sized at just 0.8% of adjusted NAV and 0.55% of total assets, a five-year, three-phase program validates the model for US$1m, scales it for US$10m, and builds a global network plus IP-licensing platform for the remaining US$20m. Any phase failing is financially immaterial; the full program succeeding could eventually contribute a profit pool half the size of the Group's FY2019 peak.
投入规模仅占经调整NAV约0.8%、总资产约0.55%：五年三阶段——US$100万验证模型，US$1,000万商业化扩张，US$2,000万建成全球网络与IP授权平台。任何阶段失败财务影响可忽略；全部成功则最终可贡献相当于集团FY2019盈利峰值一半规模的新利润池。
FEC is cutting debt; large capex is off the table. US$30m spread over 5 years averages US$6m/yr — fundable from operating cash flow (FY2026 CFO: HK$3.0bn) without touching the liability stack.
集团正在压降负债，大额资本开支不可取。US$3,000万分5年投放年均仅US$600万——可由经营现金流（FY2026经营现金流30.4亿港元）覆盖，完全不动负债端。
Phase 0 is a cheap real option: US$1m resolves whether the 73.5% margin holds in-field. If it does, phases 1–2 proceed; if not, total write-off equals 0.03% of total assets. Asymmetric payoff, capped downside.
Phase 0是一张廉价的实物期权：US$100万即可验证73.5%毛利率能否在田间成立。成立则推进Phase 1–2；不成立则全部核销仅占总资产0.03%。收益不对称、下行封顶。
Hong Kong peers have validated agtech as a re-rating lever for discount-traded developers. Tissue-culture coffee is globally first-mover territory with a limited window — the entry price rises once the model is publicly proven.
香港同业已验证农业科技作为折让股重估杠杆的有效性。咖啡组培为全球首创、先发窗口有限——一旦模型被公开验证，入场成本将显著上升。